N,N'-Bis-(4-chloro-benzyl)-isophthalamide | 449790-36-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N,N'-Bis-(4-chloro-benzyl)-isophthalamide
• 英文别名: N~1~,N~3~-bis(4-chlorobenzyl)isophthalamide；1-N,3-N-bis[(4-chlorophenyl)methyl]benzene-1,3-dicarboxamide
• CAS: 449790-36-7
• 化学式: C₂₂H₁₈Cl₂N₂O₂
• mdl: MFCD03403216
• 分子量: 413.303
• InChiKey: MJKWTVKTSVKGJK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  58.2
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• Isophthalic acid derivatives as matrix metalloproteinase inhibitors
  申请人：——

  公开号：US20020156061A1

  公开（公告）日：2002-10-24

  Selective MMP-13 inhibitors are isophthalic acid derivatives of the formula 1 wherein: R 1 , R 2 , and R 3 independently are hydrogen, halo, hydroxy, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, NO 2 , NR 4 R 5 , CN, or CF 3 ; E is independently O or S; A and B independently are OR 4 or NR 4 R 5 ; each R 4 and R 5 independently are H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, (CH 2 ) n aryl, (CH 2 ) n cycloalkyl, (CH 2 ) n heteroaryl, or R 4 and R 5 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring, optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted; n is 0 to 6; or a pharmaceutically acceptable salt thereof. The compounds are useful for treating diseases in a mammal that are mediated by MMP enzymes.

  选择性MMP-13抑制剂是公式1的异苯二甲酸衍生物，其中：R1、R2和R3独立地是氢、卤素、羟基、C1-C6烷基、C1-C6烷氧基、C2-C6烯基、C2-C6炔基、NO2、NR4R5、CN或CF3；E独立地是O或S；A和B独立地是OR4或NR4R5；每个R4和R5独立地是H、C1-C6烷基、C2-C6烯基、C2-C6炔基、(CH2)n芳基、( )n环烷基、( )n杂环芳基，或者当R4和R5连同它们连接的氮一起形成一个3至8成员环，该环可以选择性地包含从O、S或NH中选择的杂原子，并且可以被取代或未取代；n为0至6；或其药学上可接受的盐。这些化合物对于治疗由MMP酶介导的哺乳动物疾病是有用的。
• Method of determining potential allosterically-binding matrix metalloproteinase inhibitors
  申请人：Andrianjara Charles

  公开号：US20050004126A1

  公开（公告）日：2005-01-06

  Compounds are provided that bind allosterically to the catalytic domain of MMP-13 and comprise a hydrophobic group, first and second hydrogen bond acceptors and at least one, and preferably both, of a third hydrogen bond acceptor and a second hydrophobic group. Cartesian coordinates for centroids of the above features are defined in the specification. When the ligand binds to MMP-13, the first, second and third (when present) hydrogen bond acceptors bond respectively with Thr245, Thr 247 and Met 253, the first hydrophobic group locates within the S1′ channel of MMP-13 and the second hydrophobic group (when present) is relatively open to solvent. The compounds specifically inhibit the matrix metalloproteinase-13 enzyme and thus are useful for treating diseases resulting from tissue breakdown, such as heart disease, multiple sclerosis, arthritis, atherosclerosis, and osteoporosis.

  提供了一种与MMP-13催化域发生变构作用的化合物，其中包括一个疏水基团、第一和第二氢键受体以及至少一个第三氢键受体和第二个疏水基团，最好是两者都有。上述特征的笛卡尔坐标在说明书中有定义。当配体与MMP-13结合时，第一、第二和第三（存在时）氢键受体分别与Thr245、Thr 247和Met 253结合，第一疏水基团位于MMP-13的S1'通道内，第二疏水基团（存在时）相对于溶剂较为开放。这些化合物特异性地抑制了基质金属蛋白酶-13酶，因此可用于治疗由组织分解引起的疾病，如心脏病、多发性硬化症、关节炎、动脉粥样硬化和骨质疏松症。
• ISOPHTHALIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS
  申请人：Warner-Lambert Company LLC

  公开号：EP1362028A2

  公开（公告）日：2003-11-19
• COMBINATION OF AN ALLOSTERIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 THAT IS NOT CELECOXIB OR VALDECOXIB
  申请人：Warner-Lambert Company LLC

  公开号：EP1531904A1

  公开（公告）日：2005-05-25
• COMBINATION OF AN ALLOSTERIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH CELECOXIB OR VALDECOXIB
  申请人：WARNER-LAMBERT COMPANY LLC

  公开号：EP1536786A1

  公开（公告）日：2005-06-08